Figure 2.MB treatment upregulates β-catenin signaling in HFSCs. (A) Growth curve of control and MB-treated HFSCs over 12 days, showing enhanced proliferation upon MB treatment, determined by manual cell counting. (B) Cell viability of Control and MB-treated HFSCs at day 15, assessed by XTT assay. (*** p<0.0001). (C) Intracellular ROS levels in control and MB-treated HFSCs at day 15, determined by DCFDA staining and quantified using flow cytometry. (** p<0.0001) (D) Representative immunoblots of total and active β-catenin expression in control and MB-treated HFSCs at day 15. (E) Densitometric quantification of the active/total β-catenin ratio demonstrates a significant increase following MB treatment. (**** p<0.0001).
